NeuroPace to Present at 25th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc., a recognized innovator in the medical device industry, has announced its participation in the upcoming 25th Annual Needham Virtual Healthcare Conference. The company, which is dedicated to improving the lives of individuals living with epilepsy, will have its management team deliver a formal presentation and engage in investor meetings during the event. This announcement reflects NeuroPace’s continued commitment to transparency, investor engagement, and advancing awareness of its cutting-edge neurological technologies.
Event Details and Presentation Timing
The presentation by NeuroPace’s management team is scheduled for Tuesday, April 14, 2026. It will take place at 1:30 p.m. Eastern Time (ET), which corresponds to 10:30 a.m. Pacific Time (PT). This session will form part of the broader Needham Virtual Healthcare Conference, an annual event that brings together leading healthcare companies, investors, analysts, and industry experts to discuss innovations, trends, and investment opportunities within the healthcare sector.
In addition to the formal presentation, NeuroPace’s leadership team will host a series of investor meetings throughout the conference. These meetings are designed to provide a more personalized setting for discussions, enabling deeper engagement with institutional investors and analysts interested in the company’s performance and long-term growth strategy.
Significance of the Needham Healthcare Conference
The Needham Virtual Healthcare Conference is widely regarded as an important platform within the healthcare investment community. It provides participating companies with an opportunity to present their business models, highlight recent developments, and outline future plans. For investors and analysts, the conference serves as a valuable venue to gain insights into emerging technologies, market dynamics, and company-specific strategies.
NeuroPace’s participation in this prestigious event underscores its position as a key player in the neurological medical device space. By presenting at such a high-profile conference, the company aims to reinforce its leadership role and communicate its progress in addressing unmet needs in epilepsy treatment.
NeuroPace’s Mission and Focus
At the core of NeuroPace’s operations is a mission to transform the lives of people living with epilepsy. Epilepsy is a chronic neurological disorder characterized by recurrent seizures, affecting millions of individuals worldwide. While medications can help many patients manage their condition, a significant portion continues to experience uncontrolled seizures despite treatment.
NeuroPace focuses on developing advanced, technology-driven solutions to address this gap. The company is best known for its innovative approach to responsive neurostimulation, a method that combines real-time monitoring of brain activity with targeted therapeutic intervention. This approach represents a shift from traditional treatment methods, offering a more personalized and adaptive solution for patients.
Innovative Technology and Patient Impact
NeuroPace’s flagship system is designed to continuously monitor electrical activity in the brain. When abnormal patterns that may lead to a seizure are detected, the device delivers targeted stimulation intended to normalize brain activity and prevent the seizure from occurring or reduce its severity.
This responsive approach is particularly significant because it adapts to each patient’s unique neurological patterns. Over time, the system collects and analyzes data, enabling physicians to refine treatment strategies and optimize outcomes. This data-driven model not only enhances the effectiveness of therapy but also contributes to a deeper understanding of epilepsy as a condition.
For patients who have not found success with traditional treatments, such innovations can be life-changing. Improved seizure control can lead to greater independence, better quality of life, and reduced risks associated with frequent seizures.
What to Expect from the Presentation
During the conference presentation, NeuroPace’s management team is expected to provide updates on several key areas of the business. These may include recent clinical data, advancements in product development, and progress in commercialization efforts. The team may also discuss strategic initiatives aimed at expanding the company’s market presence and increasing adoption of its technology.
Additionally, the presentation may cover financial performance highlights and long-term growth plans. Investors typically look for insights into revenue trends, market opportunities, and the company’s competitive positioning within the medical device industry.
The session will also likely emphasize the company’s commitment to innovation and its ongoing efforts to improve patient outcomes through research and development.
Investor Engagement and Meetings
Beyond the formal presentation, NeuroPace’s participation in investor meetings during the conference plays a crucial role in fostering relationships with the financial community. These meetings provide an opportunity for more detailed discussions about the company’s operations, strategy, and outlook.
Investors often use these sessions to ask specific questions, gain clarity on financial metrics, and better understand the company’s vision. For NeuroPace, this direct engagement helps build trust, enhance transparency, and strengthen its reputation among stakeholders.
Webcast Accessibility and Replay Availability
To ensure broad access to its presentation, NeuroPace will provide a live webcast of the session. This allows interested parties, including investors, analysts, and members of the public, to view the presentation in real time from any location.
For those unable to attend the live session, a replay of the webcast will be made available for 30 days following the event. The replay can be accessed through the Events & Presentations section of NeuroPace’s investor relations
This extended availability ensures that stakeholders have ample time to review the content and stay informed about the company’s latest updates.
Commitment to Transparency and Communication
Providing both a live webcast and a replay reflects NeuroPace’s commitment to open communication and accessibility. In today’s digital age, virtual events and online resources have become essential tools for engaging with a global audience.
By leveraging these platforms, NeuroPace ensures that its message reaches a wide range of stakeholders, regardless of geographic location. This approach not only enhances investor relations but also supports the company’s broader goal of raising awareness about its innovative solutions.
NeuroPace’s upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference represents a significant opportunity for the company to showcase its advancements in epilepsy treatment and engage with the investment community. Through its innovative technology, patient-focused mission, and commitment to transparency, NeuroPace continues to position itself as a leader in the neurological medical device field
As the healthcare industry evolves and the demand for personalized, data-driven treatments grows, NeuroPace remains at the forefront of innovation. Its participation in this conference highlights both its progress to date and its ongoing dedication to improving the lives of individuals living with epilepsy.
Stakeholders and interested viewers are encouraged to attend the live webcast or access the replay to gain deeper insights into the company’s work and future direction.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
